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ABSTRACT
Arginine-glycine-aspartic acid (RGD) peptides preferentially bind to avb3 integrin, an integrin expressed
on newly formed endothelial cells and on various tumor cells. When labeled with b-emitting radionu-
clides, these peptides can be used for peptide-receptor radionuclide therapy of malignant tumors. These
studies aimed to investigate whether tumor targeting and tumor therapy could be optimized by dose frac-
tionation.
The RGD-peptide DOTA-E-[c(RGDfK)]2 was labeled with 111In for biodistribution experiments and
with 90Y for therapy experiments. In mice with NIH:OVCAR-3 ovarian carcinoma xenografts, optimal tu-
mor uptake was obtained at peptide doses up to 1.0 mg (4.8 %ID/g). A peptide dose of 5 mg, required to
administer the maximum tolerable dose (MTD) 90Y-DOTA-E-[c(RGDfK)]2, was administered as 5 por-
tions of 1.0 mg. Tumor uptake of the fifth portion was significantly higher than that of the single 5.0 mg
portion (3.3 %ID/g versus 2.1 %ID/g). The therapeutic efficacy of 37 MBq 90Y-DOTA-E-[c(RGDfK)]2
(1 3 5.0 mg) was compared with that of 37 MBq administered in five equal portions (5 3 1.0 mg). No
difference in tumor growth between the fractionated and the nonfractionated therapy was observed. In
conclusion, dose fractionation resulted in higher radiation doses. However, therapeutic efficacy of the ra-
diolabeled peptide was not significantly improved by dose fractionation.
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INTRODUCTION
Integrins are a group of adhesion molecules con-
sisting of two noncovalently bound transmem-
branous subunits (a and b). Integrin avb3 medi-
ates cellular adhesion to extracellular matrix
proteins (e.g., vitronectin, fibrinogen, laminin,
collagen) through exposed tripeptide arginine-
glycine-aspartic acid (RGD) amino-acid moi-
eties.1 Integrin avb3 is preferentially expressed
on proliferating endothelial cells.2 For their
growth beyond a certain size, tumors are depen-
dent on the formation of new blood vessels from
preexisting capillaries (angiogenesis) and thus
avb3 is expressed on the blood vessels of most
growing tumors.3—5 In addition, avb3 is expressed
on various tumor cell types (ovarian cancer, neu-
roblastoma, breast cancer, melanoma, and oth-
ers). Due to the restricted expression of avb3 in
tumors, avb3 is considered a suitable membrane
structure for tumor targeting.6
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The potential of avb3-binding peptides to serve
as vehicles for targeting tumors with radionu-
clides has been investigated by several groups.
Haubner et al. studied two radioiodinated cyclic
pentapeptides (c(RGDyV) and c(RGDfY); IC50 5
2 nM) in nude mice with various tumors.7 Tumor
uptake peaked 10 minutes after injection (3.50 6
0.73 %ID/g). Both peptides mainly cleared via
the hepatobiliary route. Subsequently, they syn-
thesized a glycosylated version of c(RGDyK) that
cleared predominantly via the kidneys.8 This
compound (IC50 5 40 nM) had a longer circula-
tory half-life and a significantly reduced uptake
in the liver (2 versus 10 %ID/g at 1 hour postin-
jection [p.i.]). Most importantly, the glycosylated
RGD-peptide had a clearly higher uptake in the
tumor (3.0 6 0.31 %ID/g versus 0.92 6 0.16
%ID/g at 4 hour p.i.). Van Hagen et al. studied
the cyclic peptide c(RGDyK) conjugated with
DTPA.9 Uptake of the 111In-labeled peptide in
CA20948 pancreatic tumors in rats amounted to
0.2 %ID/g at 24 hour p.i., while at this timepoint,
the peptide was almost completely cleared from
the blood (0.003 %ID/g).
In our previous studies, we have shown that the
radiolabeled c(RGDfK)-peptides specifically ac-
cumulated in avb3-positive ovarian cancer
xenografts in athymic mice.10 The dimeric RGD
peptide was retained better in the tumor than the
monomeric RGD peptide.11 The uptake of 111In-
DOTA-E-[c(RGDfK)]2 in subcutaneous (s.c.)
OVCAR-3 tumors peaked at 7.5 %ID/g 2 hour
after intravenous injection. A single injection of
this peptide labeled with 90Y (37 MBq/mouse)
caused a significant growth delay of the tumors.
In the present study, the optimal peptide dose for
peptide radionuclide therapy with the dimeric
RGD peptides was determined. In addition, the
effect of rapid dose fractionation on the radiation
dose guided to the tumors and on the therapeutic
efficacy was studied.
MATERIALS AND METHODS
Radiolabeling of the RGD Peptide
The synthesis and characterization of the dimeric
cyclic RGD peptide E-[c(RGDfK)]2 conjugated
with the chelator 1,4,7,10-tetraazadodecane-
N,N9,N0,N--tetraacetic acid (DOTA) was de-
scribed previously.10,12,13 The peptide has a high
affinity for the avb3 integrin (IC50 5 0.9 nM).
DOTA-E-[c(RGDfK)]2 was radiolabeled with
111In to obtain 111In-DOTA-E-[c(RGDfK)]2.
Briefly, 250 mg DOTA-E-[c(RGDfK)]2 was dis-
solved in 4.5 mL of 0.25 M ammoniumacetate
buffer, pH 7.0 and 160 MBq 111InCl3 (Mallinck-
rodt, Petten, The Netherlands) was added. The
mixture was heated for 15 minutes at 100¡C. The
radiochemical purity was determined by reversed-
phase high-performance liquid chromatography
(RP-HPLC) (HP 1100 series, Hewlett Packard,
Palo Alto, CA) using a C18 column (RX-C18,
4.6 3 250 mm, Zorbax) eluted with an isocratic
eluent (13% acetonitrile in 25 mM phosphate
buffer, pH 6.0) at 1.0 mL/minute. The radio-
activity of the eluate was monitored using an 
in-line radiodetector (Radiomatic Flo-One Beta
series A-500, Packard BioScience, Zellik, 
Belgium).
90Y-DOTA-E-[c(RGDfK)]2 was prepared by
adding 2775 MBq 90YCl3 (Perkin Elmer, Boston,
MA) to 375 mg of DOTA-E-[c(RGDfK)2 dis-
solved in 1.75 mL of 0.25 M ammoniumacetate
buffer, pH 6.0. The mixture was heated at 100¡C
for 15 minutes. Quality control was carried out
as described for the 111In-labeled peptide. The
scrambled sequence control peptide DOTA-E-
[c(RGKfD)]2 served as a control in the therapy
experiments and was radiolabeled with 90YCl3
analogously.
Animal Model
In our animal model, 0.2 mL of a cell suspension
of NIH:OVCAR-3 human ovarian carcinoma
cells (5 3 107 cells/mL) was injected s.c. in the
right flank of 6—8 week-old female nude BALB/c
mice. The NIH:OVCAR-3 tumor cells express
the avb3 integrin. Two (2) weeks after inocula-
tion of the tumor cells, when the diameter of the
tumors was 6—8 mm, the mice were i.v. injected
with the radiolabeled peptides via the tail vein.
Biodistribution Studies
In these experiments, the effect of the peptide
dose escalation and the effect of peptide dose
fractionation on the biodistribution of the radio-
labeled peptide was determined.
Five groups of five mice received 0.5, 1.0, 2.0,
5.0, or 10 mg of the DOTA-E-[c(RGDfK)]2 pep-
tide labeled with 0.4 MBq 111In (dose escalation).
Two (2) hours after injection of the radiolabeled
peptide, the mice were euthanized with CO2/O2.
Blood was collected by cardiac puncture, and tis-
sues (tumor, muscle, lung, spleen, kidney, liver,
small intestine) were dissected, counted, and
weighed.
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The effect of dose fractionation on the bio-
distribution of 111In-DOTA-E-[c(RGDfK)]2 was
studied in two groups of mice who received four
injections with 1 mg of nonradioactive DOTA-E-
[c(RGDfK)]2 with intervals of 1 hour or 2 hour.
One (1) or 2 hours after the fourth injection, the
mice in these groups received 1 mg of DOTA-E-
[c(RGDfK)]2 labeled with 0.4 MBq 111In. Two
(2) hours after injection of the radiolabeled pep-
tide, the mice were euthanized with CO2/O2.
Blood was collected by cardiac puncture, and tis-
sues (tumor, muscle, lung, spleen, kidney, liver,
small intestine) were dissected and weighed.
The activity in tissues and injection standards
was measured in a shielded well-type scintilla-
tion gamma counter (Wizard, Pharmacia, Turku,
Finland) and expressed as %ID/g.
Peptide-Receptor Radionuclide Therapy
The therapeutic efficacy of 37 MBq 90Y-DOTA-
E-[c(RGDfK)]2 (specific activity: 7.4 MBq/mg)
administered as one bolus injection was com-
pared to the therapeutic efficacy of the same dose
of 90Y-DOTA-E-[c(RGDfK)]2 administered in
five equal portions. Four groups of 10 mice with
s.c. NIH:OVCAR-3 tumors were used in this ex-
periment (Groups A—D). Group A received 37
MBq 90Y-DOTA-E-[c(RGDfK)]2 (peptide dose:
5.0 mg) as a single bolus injection (0.2 mL).
Group B received the same dose of 90Y-DOTA-
E-[c(RGDfK)]2 administered in 5 equal portions
(5 3 7.4 MBq; 5 3 1.0 mg) with a 1-hour in-
terval between the five injections. The mice 
in group C received 5 equal doses of the scram-
bled sequence control peptide 90Y-DOTA-E-
[c(RGKfD)]2 (5 3 7.4 MBq, 5 3 1.0 mg, 1-hour
interval). The mice in group D received 5 subse-
quent injections with nonradioactive DOTA-E-
[c(RGKfD)]2 peptide (5 3 1.0 mg, 1-hour inter-
val) and also a served as a control group.
The size of the tumors was measured twice
weekly in 3 dimensions using a caliper. The vol-
ume was estimated assuming the tumors were
elipsoids, using the formula: volume 5 4/3p 3
1/2 length 3 1/2 width 3 1/2 height. At the time
of the injection the volume of the s.c. tumors
ranged from 27 to 150 mm3. When the volume
of the tumors exceeded 2 cm3, the mice were
taken out of the experiment and euthanized.
Statistical Analysis
Statistical analysis was performed using a Graph-
Pad Prism 3.0 (GraphPad Software, San Diego,
CA). The biodistribution data were analyzed us-
ing the one-way analysis of variance ANOVA
test. The level of significance was set at p 5 0.05.
If p , 0.05, Tukey-Kramer multiple comparisons
post-tests were performed.
RESULTS
Radiolabeled Peptides
RP-HPLC analysis indicated that the radiochem-
ical purity of DOTA-E-[c(RGDfK)]2 labeled with
111In and 90Y was 96% and 95%, respectively.
The avb3 binding capacity of the 111In-labeled
peptide was confirmed in an in vitro cell binding
assay on IGROV-1 human ovarian carcinoma
cells as described previously.10
Peptide-Dose Escalation Study
The biodistribution of 111In-DOTA-E-[c(RGDfK)]2
in athymic mice with s.c. OVCAR-3 tumors at a
peptide dose of 1.0 mg per mouse is shown in
Figure 1. Two (2) hours after injection, the high-
est activity concentration was found in the tumor:
4.73 6 0.65 %ID/g. The 111In-labeled peptide
cleared very rapidly from the blood (0.08 %ID/g,
2 hour p.i.), and consequently the tumor-to-blood
ratio in these mice was relatively high (63 6 5).
The effect of the peptide dose on the biodistri-
bution of 111In-DOTA-E-[c(RGDfK)]2 is shown
in Table 1. Highest uptake in the tumor was found
at peptide doses of 0.5 and 1.0 mg (4.87 6 0.60
%ID/g and 4.73 6 0.65 %ID/g, p . 0.05) (Fig.
2). Uptake at peptide doses of 2.0, 5.0, and 10 mg
(3.20 6 0.26 %ID/g, 2.07 6 0.46 %ID/g, 1.54 6
0.15 %ID/g, respectively) was significantly lower
(p , 0.01), most likely due to saturation of ac-
cessible avb3 integrin expressed in the tumor.
The uptake of 111In-DOTA-E-[c(RGDfK)]2 in
the normal tissues (muscle, lung, liver, spleen,
and intestine) also was reduced at the higher pep-
tide doses, suggesting that the localization of the
peptide in these normal tissues was also recep-
tor-mediated and saturable (Table 1).
Interestingly, when fractionating the 5.0 mg
peptide dose in 5 fractions of 1.0 mg each, the
uptake in tumor of the last 1.0-mg dose was
higher than that of the 5.0-mg dose bolus injec-
tion (3.18 6 0.56 %ID/g versus 2.07 6 0.46
%ID/g, p , 0.05). However, the tumor uptake of
the last fraction of the fractionated dose was sig-
nificantly lower than that of a single dose of 1.0
mg (3.18 6 0.56 %ID/g versus 4.73 6 0.65
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%ID/g, p , 0.01). The uptake of the fractionated
dose was not affected by the time interval be-
tween the injections (1 hour or two h, p . 0.05).
Peptide-Receptor Radionuclide Therapy
The MTD of 90Y-DOTA-E-[c(RGDfK)]2 in this
mouse model is 37 MBq per mouse as determined
previously. The maximum specific activity of
90Y-labeled DOTA-E-[c(RGDfK)]2 is 7.4 MBq/
mg. Therefore, the MTD of the peptide has to be
administered with a peptide dose of at least 5.0
mg. The biodistribution experiments indicated
that 5.0 mg of peptide can be targeted more effi-
ciently to the OVCAR-3 tumor in this mouse
model when administered as a fractionated dose
(5 3 1.0 mg). Therefore, the therapeutic efficacy
of a single bolus injection of 37 MBq 90Y-labeled
DOTA-E-[c(RGDfK)]2 was compared to that of
the same-activity dose administered as five sub-
sequent injections with a 1-hour time interval in
a peptide-receptor radionuclide therapy experi-
ment (Fig. 3).
Dose fractionation of the activity dose of 37
MBq of 90Y- DOTA-E-[c(RGDfK)]2 in five
equal portions did not improve the growth-inhi-
bitory effect of the radionuclide therapy com-
pared to therapy with 37 MBq of 90Y-DOTA-E-
[c(RGDfK)]2 administered in one injection of 5.0
mg of peptide. The growth rate of the tumors in
both of these groups was significantly delayed
compared to the growth of the tumors in the mice
that received 90Y-labeled scrambled control pep-
tide or nonradioactive peptide.
DISCUSSION
The present study aimed to optimize peptide-re-
ceptor radionuclide therapy with a 90Y-labeled
dimeric cyclic RGD peptide using rapid-dose
fractionation. The maximum specific activity of
the 90Y-labeled DOTA-E-[c(RGDfK)]2 peptide
that we use for peptide receptor radionuclide ther-
apy is 7.4 MBq/mg, while a total activity dose of
37 MBq can be administered safely to mice.
Therefore, a 37 MBq dose contains at least 5.0
mg of the DOTA-E-[c(RGDfK)]2 peptide. How-
ever, the peptide dose escalation study indicated
that, at peptide doses exceeding 1.0 mg/mouse,
the uptake in the tumor decreased, most likely
due to saturation of the avb3 binding sites in the
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Figure. 1. Biodistribution of 111In- DOTA-E-[c(RGDfK)]2
peptide in athymic mice with subcutaneous OVCAR-3 tu-
mors 2 hour after injection at a peptide dose of 1.0 mg.
Table 1. Biodistribution (%ID/g 6 SD) of 111In- DOTA-E-[c(RGDfK)]2 at Various Peptide Doses in Athymic Mice with
Subcutaneous OVCAR-3 Tumors 2 H after Injection
Dose
5 3 1.0 mg 5 3 1.0 mg
Organ 0.5 mg 1.0 mg 2.0 mg 5.0 mg 10 mg 1-h interval 2-h interval
Blood 0.12 6 0.02 0.08 6 0.01 0.08 6 0.01 0.06 6 0.01 0.06 6 0.01 0.05 6 0.01 0.05 6 0.01
Muscle 0.42 6 0.02 0.28 6 0.03 0.27 6 0.07 0.13 6 0.01 0.16 6 0.08 0.29 6 0.11 0.28 6 0.06
Tumor 4.87 6 0.60 4.73 6 0.65 3.20 6 0.26 2.07 6 0.46 1.54 6 0.15 3.28 6 0.60 3.18 6 0.56
Lung 0.97 6 0.07 1.11 6 0.09 0.72 6 0.08 0.47 6 0.09 0.44 6 0.06 0.70 6 0.10 0.64 6 0.01
Spleen 2.03 6 0.08 1.99 6 0.11 1.50 6 0.20 1.14 6 0.15 0.79 6 0.03 1.58 6 0.12 1.23 6 0.10
Kidney 2.91 6 0.11 2.93 6 0.28 2.37 6 0.36 2.04 6 0.18 2.26 6 0.12 2.08 6 0.14 1.93 6 0.25
Liver 2.18 6 0.08 2.03 6 0.26 1.55 6 0.24 0.93 6 0.10 0.70 6 0.08 1.50 6 0.19 1.17 6 0.14
Intestine 3.46 6 0.37 3.08 6 0.92 2.51 6 0.39 1.61 6 0.30 1.06 6 0.14 2.25 6 0.30 1.93 6 0.29
In the two groups of mice that received a fractionated dose (5 3 1.0 mg), the biodistribution of the fifth fraction of the dose
is shown.
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tumor. Similarly, the uptake in most normal tis-
sues tested (lung, spleen, kidney, liver, and in-
testine) was significantly lower at the higher pep-
tide doses. This observation was in line with
earlier studies in which we showed that part of
the uptake of the peptide in normal tissues can
be blocked with an excess of cold peptide,10 in-
dicating that the uptake in these tissues is sat-
urable. Whether this is due to expression of avb3
integrin in these tissues remains to be investigated.
When the 5.0-mg dose was administered in five
equal portions with a 1- or 2-hour time interval,
the uptake in the tumor of the last 1.0-mg portion
(3.2 6 0.2 %ID/g) was significantly higher than
that of the 5.0-mg dose injected as a bolus (2.1 6
0.5 %ID/g). These data indicate that the uptake
of the 5 3 1.0 mg—dose was even higher, because
the uptake of the first 1.0-mg fraction in the tu-
mor was 4.7 6 0.6 %ID/g. These results indicate
that the mean uptake of the 5 3 1.0—mg dose is
approximately 4.0 %ID/g, being the mean tumor
uptake of the first and the fifth dose. Thus, the
biodistribution study showed that rapid-dose
fractionation can increase the uptake of the radi-
olabeled peptide almost twofold. These data sug-
gest that within 1 hour after targeting the avb3
binding sites in the tumor with the RGD-peptide,
new avb3 binding sites are available for binding
newly administered RGD-peptide.
Despite the fact that peak tumor uptake of the
radiolabeled peptide was higher when the frac-
tionated dose scheme was applied, the therapeu-
tic effect of 37 MBq 90Y-DOTA-E-[c(RGDfK)]2
was not enhanced significantly when adminis-
tered as 5 equal fractions of 7.4 MBq. This could
be due to the fact that the therapeutic effect of
90Y-DOTA-E-[c(RGDfK)]2 administered as a
single bolus was considerable.
Various studies have investigated the potential
of dose fractionation in radionuclide therapy. The
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Figure. 2. Tumor uptake of 111In-DOTA-E-[c(RGDfK)]2
peptide in athymic mice with subcutaneous OVCAR-3 tu-
mors 2 hours after injection at various peptide doses. Note
that optimal tumor uptake is obtained with a peptide dose
of 0.5 and 1.0 mg. At higher peptide doses, the uptake in the
tumor was lower due to saturation of the avb3 binding sites
in the tumor. In addition, the uptake in the tumor of the 
fifth fraction of five 1.0-mg doses of DOTA-E-[c(RGDfK)]2
(with 1- or 2-hour time intervals) is shown.
Figure. 3. Growth curves of the s.c. OVCAR-3 tumors in the four groups of mice (7—10 mice/group) after intravenous injec-
tion of 37 MBq 90Y-DOTA-E-[c(RGDfK)]2 (5.0 mg) (s), 5 3 7.4 MBq 90Y-DOTA-E-[c(RGDfK)]2 (5 3 1.0 mg) (d), 5 3 7.4
MBq control peptide 90Y-DOTA-E-[c(RGKfK)]2 (5 3 1.0 mg) (j), or nonradioactive DOTA-E-[c(RGDfK)]2 (5 3 1.0 mg) (u).
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rationale and the design of these studies varied
largely. Several studies aimed to overcome het-
erogeneity of intratumoral distribution of the ra-
dionuclide and the consequent nonuniformity of
tumor radiation doses.14,15 Other studies aimed
to reduce marrow toxicity and thus to increase
the total radioactivity dose that can be adminis-
tered.16,17 Only a few studies aimed to enhance
to radiation dose to the tumor and thus to enhance
the therapeutic effect of the same activity dose
administered as multiple injections. In mice with
HeLa xenografts, the tumor targeting with 22
MBq 125I-labeled anti-cytokeratin monoclonal
antibody administered as one, three, or ten injec-
tions was investigated.18 In contrast with our
findings, these investigators found reduced up-
take in the tumors when the dose was adminis-
tered in multiple injections. However, in that
study the time interval between the injections was
much longer and the antibody protein dose did
not saturate the target antigen in the tumor. Goel
et al. described a study in mice with LS174T tu-
mors in which the researchers compared the ther-
apeutic efficacy of an activity dose of 37 MBq 131I-
labeled CC49 antibody construct either as a single
bolus or as 4 injections (4 3 0.25 MBq) with a 1-
day time interval.19 They found that the therapeu-
tic efficacy of the fractionated dose was signifi-
cantly higher than that of the single injection.
In conclusion, the present study shows that rapid-
dose fractionation can improve the targeting of
avb3-expressing tumors with radiolabeled dimeric
cyclic RGD peptide. Our studies suggest that 1 hour
after targeting the avb3 binding sites in the tumor
with the RGD-peptide, new avb3 binding sites are
available again for binding RGD peptides.
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